Patents by Inventor Bradley L. Pentelute

Bradley L. Pentelute has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240336649
    Abstract: The disclosure relates to covalent protein dimers of MYC, MAX, and Omomyc; pharmaceutical compositions comprising the covalent protein dimers; methods of making the covalent protein dimers; and methods of treating disorders associated with MYC dysregulation (e.g., cancer) with the covalent protein dimers.
    Type: Application
    Filed: June 17, 2022
    Publication date: October 10, 2024
    Inventors: ANDREI LOAS, BRADLEY L. PENTELUTE, SEBASTIAN POMPLUN, MUHAMMAD JBARA, CARLY KATHERINE SCHISSEL, JACOB JOSHUA LEE RODRIQUEZ, STEPHEN LEFFLER BUCHWALD, ANN BOIJA, ISAAC KLEIN, SUSANA WILSON HAWKEN, CHARLES HAN LI
  • Publication number: 20240254186
    Abstract: Disclosed are polypeptides, compositions, and methods useful for activating a glucagon-like peptide-1 (GLP-1) receptor and treating or preventing diseases or disorders at least partially mediated by glucagon-like peptide 1 (GLP-1).
    Type: Application
    Filed: December 13, 2023
    Publication date: August 1, 2024
    Inventors: Tomi K. SAWYER, Joseph AUDIE, David J. DILLER, Valentin GRIBKOFF, Bradley L. PENTELUTE, Solimar G. SANTIAGO, Jonathon R. SAWYER, Allison Ackerman SHRIER, Jon T. SWANSON, Dinara S. GUNASEKERA
  • Patent number: 12043646
    Abstract: Methods and systems for control of solid phase peptide synthesis are generally described. Control of solid phase peptide synthesis involves the use of feedback from one or more reactions and/or processes (e.g., reagent removal) taking place in the solid phase peptide synthesis system. In some embodiments, a detector may detect one or more fluids flowing across a detection zone of a solid phase peptide synthesis system and one or more signals may be generated corresponding to the fluid(s). For instance, an electromagnetic radiation detector positioned downstream of a reactor may detect a fluid exiting the reactor after a deprotection reactor and produce a signal(s). In some embodiments, based at least in part on information derived from the signal(s), a parameter of the system may be modulated prior to and/or during one or more subsequent reactions and/or processes taking place in the solid phase peptide synthesis system.
    Type: Grant
    Filed: December 20, 2022
    Date of Patent: July 23, 2024
    Assignee: Massachusetts Institute of Technology
    Inventors: Dale Arlington Thomas, III, Alexander James Mijalis, Bradley L. Pentelute, Mark David Simon, Surin Mong
  • Patent number: 12030888
    Abstract: The present disclosure provides compounds of Formula I, methods of preparing the compounds, compositions, kits, and methods of using the compounds for treating or preventing microbial infections.
    Type: Grant
    Filed: December 23, 2021
    Date of Patent: July 9, 2024
    Assignee: Massachusetts Institute of Technology
    Inventors: Mohammad Movassaghi, Bradley L. Pentelute, Carly Schissel, Kyan Anthony D'Angelo
  • Patent number: 11878996
    Abstract: Systems and processes for performing solid phase peptide synthesis are generally described. Solid phase peptide synthesis is a known process in which amino acid residues are added to peptides that have been immobilized on a solid support. In certain embodiments, the inventive systems and methods can be used to perform solid phase peptide synthesis quickly while maintaining high yields. Certain embodiments relate to processes and systems that may be used to heat, transport, and/or mix reagents in ways that reduce the amount of time required to perform solid phase peptide synthesis.
    Type: Grant
    Filed: December 18, 2020
    Date of Patent: January 23, 2024
    Assignee: Massachusetts Institute of Technology
    Inventors: Mark David Simon, Bradley L. Pentelute, Andrea Adamo, Patrick Louis Heider, Klavs F. Jensen
  • Patent number: 11753633
    Abstract: Embodied herein are engineered fusion proteins that bind and target nociceptor neurons, compositions comprising these engineered fusion proteins, and methods for treatment of pain using these engineered fusion proteins or compositions containing the engineered fusion proteins. The engineered fusion proteins contain domains derived from protein toxins such as the anthrax toxin, clostridial botulinum family of toxins, disulphide-containing toxins, and AB component type toxins.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: September 12, 2023
    Assignees: President and Fellows of Harvard College, Massachusetts Institute of Technology, IPSEN PHARMA S.A.S.
    Inventors: R. John Collier, Isaac Chiu, Bradley L. Pentelute, Keith Alan Foster, Shilpa Palan, Sai Man Liu
  • Publication number: 20230279045
    Abstract: Methods and systems for control of solid phase peptide synthesis are generally described. Control of solid phase peptide synthesis involves the use of feedback from one or more reactions and/or processes (e.g., reagent removal) taking place in the solid phase peptide synthesis system. In some embodiments, a detector may detect one or more fluids flowing across a detection zone of a solid phase peptide synthesis system and one or more signals may be generated corresponding to the fluid(s). For instance, an electromagnetic radiation detector positioned downstream of a reactor may detect a fluid exiting the reactor after a deprotection reactor and produce a signal(s). In some embodiments, based at least in part on information derived from the signal(s), a parameter of the system may be modulated prior to and/or during one or more subsequent reactions and/or processes taking place in the solid phase peptide synthesis system.
    Type: Application
    Filed: December 20, 2022
    Publication date: September 7, 2023
    Applicant: Massachusetts Institute of Technology
    Inventors: Dale Arlington Thomas, III, Alexander James Mijalis, Bradley L. Pentelute, Mark David Simon, Surin Mong
  • Publication number: 20230242558
    Abstract: Disclosed herein are compounds related to nicotinate and nicotinamide riboside and methods of making and using said compounds. Also disclosed herein are methods of making nicotinic acid mononucleoside (NAMN).
    Type: Application
    Filed: January 31, 2023
    Publication date: August 3, 2023
    Inventors: Bradley L. Pentelute, Dinara S. Gunasekera, Kevin Kong, Sabrina Johnson
  • Patent number: 11672869
    Abstract: The present invention relates to compositions and methods associated with antibody-bacterial effector translocase protein conjugates. Some aspects of the present invention relate to preventing or treating diseases using the antibody-protective antigen conjugates. Further aspects of the present invention relate to methods of chemically conjugating and synthesizing the antibody-bacterial effector translocase protein conjugates.
    Type: Grant
    Filed: August 23, 2019
    Date of Patent: June 13, 2023
    Assignee: Massachusetts Institute of Technology
    Inventors: Zeyu Lu, Bradley L. Pentelute
  • Publication number: 20230174572
    Abstract: Methods and system for solid phase peptide synthesis are provided. Solid phase peptide synthesis is a known process in which amino acid residues are added to peptides that have been immobilized on a solid support. New amino acid residues are added via a coupling reaction between an activated amino acid and an amino acid residue of the immobilized peptide. Amino acids may be activated using, e.g., a base and an activating agent. Certain inventive concepts, described herein, relate to methods and systems for the activation of amino acids. These systems and methods may allow for fewer side reactions and a higher yield compared to conventional activation techniques as well as the customization of the coupling reaction on a residue-by-residue basis without the need for costly and/or complex processes.
    Type: Application
    Filed: May 18, 2022
    Publication date: June 8, 2023
    Applicant: Massachusetts Institute of Technology
    Inventors: Dale Arlington Thomas, III, Alexander James Mijalis, Bradley L. Pentelute, Mark David Simon, Andrea Adamo, Patrick Louis Heider, Klavs F. Jensen
  • Publication number: 20230173086
    Abstract: Disclosed are conjugates, comprising a peptide moiety, a linker, and an active moiety. Also disclosed are methods of using the conjugates for treating a disease, inducing antigen-specific immunotolerance to the active moiety, or extending the half-life of the active moiety.
    Type: Application
    Filed: October 19, 2022
    Publication date: June 8, 2023
    Inventors: Bradley L. Pentelute, Tomi K. Sawyer, Dinara S. Gunasekera, Solimar G. Santiago, Jonathon R. Sawyer
  • Publication number: 20230152316
    Abstract: The disclosure provides peptides that are useful for the prevention of infection of coronaviruses, especially SARS-CoV-2. Also described is a method reducing probability of viral infection in a human subject, comprising administering a therapeutically effective amount of the pharmaceutical composition described herein.
    Type: Application
    Filed: March 19, 2021
    Publication date: May 18, 2023
    Inventors: Bradley L. Pentelute, Genwei Zhang, Sebastian Pomplun, Alexander R. Loftis, Andrei Loas
  • Patent number: 11584776
    Abstract: Methods and systems for control of solid phase peptide synthesis are generally described. Control of solid phase peptide synthesis involves the use of feedback from one or more reactions and/or processes (e.g., reagent removal) taking place in the solid phase peptide synthesis system. In some embodiments, a detector may detect one or more fluids flowing across a detection zone of a solid phase peptide synthesis system and one or more signals may be generated corresponding to the fluid(s). For instance, an electromagnetic radiation detector positioned downstream of a reactor may detect a fluid exiting the reactor after a deprotection reactor and produce a signal(s). In some embodiments, based at least in part on information derived from the signal(s), a parameter of the system may be modulated prior to and/or during one or more subsequent reactions and/or processes taking place in the solid phase peptide synthesis system.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: February 21, 2023
    Assignee: Massachusetts Institute of Technology
    Inventors: Dale Arlington Thomas, III, Alexander James Mijalis, Bradley L. Pentelute, Mark David Simon, Surin Mong
  • Publication number: 20230015478
    Abstract: Disclosed are polypeptides, compositions, and methods useful for activating a glucagon-like peptide-1 (GLP-1) receptor and treating or preventing diseases or disorders at least partially mediated by glucagon-like peptide 1 (GLP-1).
    Type: Application
    Filed: June 14, 2022
    Publication date: January 19, 2023
    Inventors: Tomi K. Sawyer, Joseph Audie, David J. Diller, Valentin Gribkoff, Bradley L. Pentelute, Solimar G. Santiago, Jonathon R. Sawyer, Allison A. Shrier, Jon T. Swanson, Dinara S. Gunasekera
  • Publication number: 20220289750
    Abstract: The present disclosure provides compounds of Formula I, methods of preparing the compounds, compositions, kits, and methods of using the compounds for treating or preventing microbial infections.
    Type: Application
    Filed: December 23, 2021
    Publication date: September 15, 2022
    Inventors: Mohammad Movassaghi, Bradley L. Pentelute, Carly Schissel, Kyan Anthony D'Angelo
  • Publication number: 20220275021
    Abstract: Systems and processes for performing solid phase peptide synthesis are generally described. Solid phase peptide synthesis is a known process in which amino acid residues are added to peptides that have been immobilized on a solid support. In certain embodiments, the inventive systems and methods can be used to perform solid phase peptide synthesis quickly while maintaining high yields. Certain embodiments relate to processes and systems that may be used to heat, transport, and/or mix reagents in ways that reduce the amount of time required to perform solid phase peptide synthesis.
    Type: Application
    Filed: December 21, 2021
    Publication date: September 1, 2022
    Applicant: Massachusetts Institute of Technology
    Inventors: Mark David Simon, Bradley L. Pentelute, Andrea Adamo, Patrick Louis Heider, Klavs F. Jensen
  • Patent number: 11279734
    Abstract: The present invention provides novel peptides (e.g., peptides, macrocyclic peptides, mini-proteins) that modulate protein-protein interactions or salts thereof, and methods of making and using the inventive peptides. In some embodiments, the peptides are high affinity inhibitors (e.g., KD of at most 100 nM, at most 10 nM, at most 1 nM) of a protein-protein interaction. In certain embodiments, these peptides interfere with p53-MDM2 binding interactions (e.g., by binding to MDM2 (GenBankĀ® Gene ID: 4193)). In some embodiments, the peptides interfere with the dimerization of the C-terminal domain of the human immunodeficiency virus (HIV) capsid protein (C-CA), comprising residues 146-231 of the HIV capsid protein (e.g., by binding to the C-terminal domain of the HIV capsid protein (C-CA), thereby inhibiting the dimeric interface of HIV capsid protein, thereby inhibiting viral assembly).
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: March 22, 2022
    Assignee: Massachusetts Institute of Technology
    Inventors: Bradley L. Pentelute, Faycal Touti
  • Publication number: 20220033795
    Abstract: Embodied herein are engineered fusion proteins that bind and target nociceptor neurons, compositions comprising these engineered fusion proteins, and methods for treatment of pain using these engineered fusion proteins or compositions containing the engineered fusion proteins. The engineered fusion proteins contain domains derived from protein toxins such as the anthrax toxin, clostridial botulinum family of toxins, disulphide-containing toxins, and AB component type toxins.
    Type: Application
    Filed: August 13, 2021
    Publication date: February 3, 2022
    Inventors: R. John Collier, Isaac Chiu, Bradley L. Pentelute
  • Publication number: 20210290772
    Abstract: Provided herein are oligonucleotides, trimeric peptides, and peptide-oligonucleotide-conjugates. Also provided herein are methods of treating a muscle disease in a subject in need thereof, comprising administering to the subject oligonucleotides, trimeric peptides, and peptide-oligonucleotide-conjugates described herein.
    Type: Application
    Filed: July 29, 2019
    Publication date: September 23, 2021
    Inventors: Justin Wolfe, Colin M. Fadzen, Bradley L. Pentelute, Gunnar J. Hanson
  • Patent number: 11104892
    Abstract: Embodied herein are engineered fusion proteins that bind and target nociceptor neurons, compositions comprising these engineered fusion proteins, and methods for treatment of pain using these engineered fusion proteins or compositions containing the engineered fusion proteins. The engineered fusion proteins contain domains derived from protein toxins such as the anthrax toxin, clostridial botulinum family of toxins, disulphide-containing toxins, and AB component type toxins.
    Type: Grant
    Filed: May 27, 2020
    Date of Patent: August 31, 2021
    Assignees: President and Fellows of Harvard College, Massachusetts Institute of Technology
    Inventors: R. John Collier, Isaac Chiu, Bradley L. Pentelute